Oncolytics Biotech (ONCY)
(Real Time Quote from BATS)
$0.96 USD
0.00 (0.21%)
Updated Sep 9, 2024 01:06 PM ET
4-Sell of 5 4
D Value D Growth F Momentum F VGM
Oncolytics Biotech Inc. (ONCY) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$4.68 | $6.63 | $2.22 | 387.50% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Oncolytics Biotech Inc. comes to $4.68. The forecasts range from a low of $2.22 to a high of $6.63. The average price target represents an increase of 387.5% from the last closing price of $0.96.
Analyst Price Targets (6 )
Broker Rating
Oncolytics Biotech Inc. currently has an average brokerage recommendation (ABR) of 1.29 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.43 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, five are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 71.43% and 28.57% of all recommendations. A month ago, Strong Buy made up 57.14%, while Buy represented 42.86%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 4 | 4 | 4 | 4 |
Buy | 2 | 3 | 3 | 3 | 3 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.29 | 1.43 | 1.43 | 1.43 | 1.43 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/21/2024 | H.C. Wainwright & Co. | Patrick Trucchio | Strong Buy | Strong Buy |
8/5/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
5/10/2024 | Cantor Fitzgerald & Co | Louise Chen | Strong Buy | Strong Buy |
5/9/2024 | Leede Jones Gable | Douglas W Loe | Moderate Buy | Strong Buy |
4/4/2024 | Raymond James Ltd. | Rahul Sarugaser | Not Available | Moderate Buy |
2/8/2024 | Canaccord Genuity | John L Newman | Strong Buy | Strong Buy |
2/2/2024 | Maxim Group | Jason Mccarthy | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.29 |
ABR (Last week) | 1.43 |
# of Recs in ABR | 7 |
Average Target Price | $4.68 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 86 of 253 |
Current Quarter EPS Est: | -0.08 |
ONCY FAQs
Oncolytics Biotech Inc. (ONCY) currently has an average brokerage recommendation (ABR) of 1.29 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 7 brokerage firms.
The average price target for Oncolytics Biotech Inc. (ONCY) is $4.68. The current on short-term price targets is based on 3 reports.
The forecasts for Oncolytics Biotech Inc. (ONCY) range from a low of $2.22 to a high of $6.63. The average price target represents a increase of $387.50 from the last closing price of $.96.
The current UPSIDE for Oncolytics Biotech Inc. (ONCY) is 387.50%
Based on short-term price targets offered by six analysts, the average price target for Oncolytics Biotech Inc. comes to $4.68. The forecasts range from a low of $2.22 to a high of $6.63. The average price target represents an increase of 387.5% from the last closing price of $0.96.